Merck KGaA back on track with MS drug

After first getting unexpectedly stiff-armed by the FDA, Merck KGaA says that its app for the oral MS therapy cladribine has now been granted a priority review, putting it on track for a fourth-quarter decision. The German pharma company has been trailing Novartis recently in the race to the market with the world's first oral MS drug. An expert panel has already voted to endorse Novartis' Gilenia. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.